$0.70+0.06 (+9.69%)
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
Fractyl Health, Inc. in the Healthcare sector is trading at $0.70. The stock is currently near its 52-week low of $0.38, remaining 41.2% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why GUTS maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal d...
Moby summary of Fractyl Health, Inc. Common Stock's Q4 2025 earnings call
Despite a significant net loss, Fractyl Health Inc (GUTS) remains optimistic with strong cash reserves and promising regulatory feedback for its Revita device.
Fractyl Health (NASDAQ:GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its investment narrative around Revita, its endoscopic procedure aimed at helping patients maintain weight loss after stopping GLP-1 drugs. Management said recent analyses of clinical data have clarified
Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, H.C. Wainwright maintained a Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS) with an $8 price target, addressing a sharp selloff following the company’s January data release. The firm said the update triggered a 65% […]
Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.